Edition:
United States

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

78.00CHF
19 Jan 2018
Change (% chg)

CHF0.60 (+0.78%)
Prev Close
CHF77.40
Open
CHF77.45
Day's High
CHF78.25
Day's Low
CHF77.30
Volume
32,618
Avg. Vol
56,322
52-wk High
CHF95.35
52-wk Low
CHF70.10

Latest Key Developments (Source: Significant Developments)

Basilea Announces Completion Of License Agreement Extension With Pfizer
Wednesday, 10 Jan 2018 01:15am EST 

Jan 10 (Reuters) - Basilea Pharmaceutica AG ::BASILEA ANNOUNCES COMPLETION OF THE LICENSE AGREEMENT EXTENSION WITH PFIZER FOR ANTIFUNGAL CRESEMBA FOR CHINA AND ASIA PACIFIC.  Full Article

Basilea starts clinical phase 1 study in collaboration with U.S. Adult Brain Tumor Consortium ​
Wednesday, 3 Jan 2018 01:16am EST 

Jan 3 (Reuters) - Basilea Pharmaceutica Ag ::‍INITIATION OF A PHASE 1 STUDY CONDUCTED UNDER ITS CLINICAL STUDY AGREEMENT WITH ADULT BRAIN TUMOR CONSORTIUM IN U.S.​.‍BASILEA EXPECTS TO COMPLETE PHASE 1 PATIENT RECRUITMENT INTO SEPARATE GLIOBLASTOMA ARM OF ORAL STUDY IN FIRST HALF OF 2018​.  Full Article

Basilea: Ceftobiprole Gets QIDP Designation From U.S. FDA
Thursday, 21 Dec 2017 01:15am EST 

Dec 21 (Reuters) - BASILEA PHARMACEUTICA AG ::BASILEA REPORTS THAT CEFTOBIPROLE RECEIVED QIDP DESIGNATION FROM U.S. FDA FOR THE TREATMENT OF STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB).  Full Article

Basilea Extends Existing License Agreement With Pfizer For Cresemba
Friday, 1 Dec 2017 01:20am EST 

Dec 1 (Reuters) - BASILEA PHARMACEUTICA AG ::BASILEA EXTENDS EXISTING LICENSE AGREEMENT WITH PFIZER <<>> FOR ANTIFUNGAL CRESEMBA® (ISAVUCONAZOLE) TO CHINA AND ASIA PACIFIC.BASILEA UPDATES ITS FINANCIAL GUIDANCE FOR 2017 - IMPROVED RESULT EXPECTED.ELIGIBLE TO RECEIVE MILESTONE PAYMENTS OF UP TO USD 226 MILLION AND MID-TEEN ROYALTIES ON SALES.WILL RECEIVE UPFRONT PAYMENT OF USD 3 MILLION.FOR FY EXPECTS A REDUCED OPERATING LOSS OF APPROXIMATELY CHF 1 MILLION ON AVERAGE PER MONTH.FOR FY SEES LOWER OPERATING EXPENSES.  Full Article

Basilea Pharmaceutica ‍marketing authorization for Cresemba for Switzerland​
Thursday, 2 Nov 2017 02:15am EDT 

Nov 2 (Reuters) - BASILEA PHARMACEUTICA AG ::‍MARKETING AUTHORIZATION RECEIVED FOR CRESEMBA FOR SWITZERLAND​.  Full Article

Basilea announces license with Shenzhen China Resources Gosun Pharmaceutical Co
Thursday, 28 Sep 2017 01:15am EDT 

Sept 28 (Reuters) - BASILEA PHARMACEUTICA AG ::BASILEA ANNOUNCES LICENSE AGREEMENT FOR ANTIBIOTIC ZEVTERA® (CEFTOBIPROLE) WITH SHENZHEN CHINA RESOURCES GOSUN PHARMACEUTICAL CO., LTD..  Full Article

Basilea says distribution agreement with Cardiome
Tuesday, 12 Sep 2017 01:15am EDT 

Sept 12 (Reuters) - BASILEA PHARMACEUTICA AG ::BASILEA ANNOUNCES DISTRIBUTION AGREEMENT WITH CARDIOME TO COMMERCIALIZE ANTIBIOTIC ZEVTERA/MABELIO (CEFTOBIPROLE) IN EUROPE AND ISRAEL.‍BASILEA WILL RECEIVE AN UPFRONT PAYMENT OF CHF 5 MILLION​.CARDIOME GRANTED EXCLUSIVE LICENSE TO COMMERCIALIZE CEFTOBIPROLE IN MORE THAN 30 COUNTRIES IN EUROPE AND IN ISRAEL.  Full Article

Basilea reports significant progress on partnering and development programs
Thursday, 10 Aug 2017 01:18am EDT 

Aug 10 (Reuters) - Basilea Pharmaceutica AG ::Basilea reports improved financial results in half-year 2017 driven by growing product sales; significant progress on partnering and development programs.  Full Article

Basilea Pharmaceutica H1 net loss narrows to CHF 20.6 million​
Thursday, 10 Aug 2017 01:15am EDT 

Aug 10 (Reuters) - BASILEA PHARMACEUTICA AG ::‍56 PERCENT INCREASE IN TOTAL H1 REVENUE, AMOUNTING TO CHF 46.2 MILLION​.‍COMPLETED LICENSE AGREEMENT WITH PFIZER FOR CRESEMBA IN EUROPE​.CHF 253.1 MILLION IN CASH AND INVESTMENTS AS OF JUNE 30, 2017 AND A SIGNIFICANTLY REDUCED OPERATING LOSS OF CHF 17.7 MILLION IN FIRST HALF-YEAR (H1 2016: CHF 24.8 MILLION; -29%).‍REPORTED CHF 253.1 MILLION IN CASH AND INVESTMENTS AS OF JUNE 30, 2017​.UPDATES ITS FINANCIAL GUIDANCE FOR 2017.‍H1 NET LOSS NARROWS TO 20.6 CHF MILLION​.‍NOW ANTICIPATES ITS 2017 PRODUCT SALES TO BE APPROXIMATELY CHF 13 MILLION, AND A PARTICIPATION IN PARTNER SALES THROUGH ROYALTIES OF APPROXIMATELY CHF 15 MILLION​.TOTAL OPERATING EXPENSES FOR 2017, NET OF ANTICIPATED BARDA REIMBURSEMENTS, ARE ESTIMATED AT CHF 9-10 MILLION ON AVERAGE PER MONTH.  Full Article

Pfizer to have exclusive rights to distribute, commercialize CRESEMBA in Europe
Wednesday, 14 Jun 2017 01:20pm EDT 

June 14 (Reuters) - Pfizer Inc ::Pfizer receives exclusive commercialization rights in Europe for CRESEMBA, a novel treatment for potentially life-threatening fungal infections among immunocompromised patients.Pfizer will have exclusive rights to distribute and commercialize CRESEMBA in Europe, including Austria, France, Germany, Italy and UK.Pfizer will be responsible for additional CRESEMBA launches, predominantly in Europe, which are expected throughout 2017 and 2018​.Basilea will remain marketing authorization holder for CRESEMBA in European Union.  Full Article

BRIEF-Basilea starts clinical phase 1 study in collaboration with U.S. Adult Brain Tumor Consortium ​

* ‍INITIATION OF A PHASE 1 STUDY CONDUCTED UNDER ITS CLINICAL STUDY AGREEMENT WITH ADULT BRAIN TUMOR CONSORTIUM IN U.S.​